This blend combines Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective ghrelin mimetic. When used together, they synergistically stimulate growth hormone release. Dosing involves a gradual titration starting from 250 mcg Tesamorelin and 125 mcg Ipamorelin daily.
- Combines GHRH analog (Tesamorelin) with ghrelin mimetic (Ipamorelin).
- Synergistically amplifies growth hormone release.
- Typical protocol involves gradual dose titration over 8-16 weeks.
- Reconstitute with 3.0 mL bacteriostatic water for approximately 3.33 mg/mL total concentration.
- Administered via subcutaneous injection, usually once daily in the evening.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 16.7 mcg of each peptide (Tesamorelin & Ipamorelin)
- 1Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2Carefully inject the water down the inside wall of the 10 mg peptide vial, avoiding direct contact with the powder to prevent foaming.
- 3Gently swirl or roll the vial until all the peptide powder is fully dissolved; do not shake vigorously.
- 4Label the reconstituted vial with the date and concentration, then refrigerate it, protected from light. Use within 24–48 hours.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1–2 | 250 mcg Tesamorelin + 125 mcg Ipamorelin | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg Tesamorelin + 250 mcg Ipamorelin | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg Tesamorelin + 500 mcg Ipamorelin | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg Tesamorelin + 750 mcg Ipamorelin | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg Tesamorelin + 1000 mcg Ipamorelin | 180 units (1.80 mL) |
Protocol detail
| Start | Begin with 250 mcg Tesamorelin and 125 mcg Ipamorelin daily, increasing the dose incrementally every two weeks as per the schedule. |
|---|---|
| Target | Aim to reach a daily dose of 1500–2000 mcg Tesamorelin and 750–1000 mcg Ipamorelin by weeks 7–16 of the protocol. |
| Frequency | Administer once daily via subcutaneous injection. |
| Cycle Length | The recommended treatment duration is between 8 and 16 weeks. |
| Timing | Evening or bedtime administration is often preferred to align with natural nocturnal growth hormone secretion patterns. Remember to rotate injection sites. |
Overview at a glance
| Goal | To support pulsatile growth hormone (GH) release by stimulating both GHRH and ghrelin pathways. |
|---|---|
| Schedule | Daily subcutaneous injections for a duration of 8 to 16 weeks. |
| Dose Range | Tesamorelin 250–2000 mcg + Ipamorelin 125–1000 mcg daily, with gradual increases over the cycle. |
| Reconstitution | Add 3.0 mL of bacteriostatic water to a 10 mg vial, resulting in approximately 3.33 mg/mL total concentration for precise unit measurements. |
| Storage | Lyophilized powder should be refrigerated at 2–8 °C; once reconstituted, use immediately or refrigerate and use within 24–48 hours. |
How it works
Tesamorelin, a synthetic GHRH analog, stimulates the pituitary gland to release growth hormone. Ipamorelin is a ghrelin mimetic that selectively promotes GH secretion by acting on its specific receptor, without significantly affecting hormones like cortisol or prolactin. When these two peptides are administered together, they create a synergistic effect, leading to a much greater amplification of GH pulses than either peptide alone. This dual action supports natural physiological processes related to growth hormone.
Reported effects
- Enhanced pulsatile growth hormone secretion.
- Reduction in visceral fat and trunk fat (observed with Tesamorelin).
- High selectivity for GH without significant impact on other hormones (Ipamorelin).
- Potential improvements in body composition.
Reported side effects
- Injection-site reactions (redness, itching)
- Joint pain (arthralgia)
- Swelling (peripheral edema)
- Transient flushing
- Headache
Storage
Lyophilised (unmixed)
Refrigerate at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) for up to 3 months.
After reconstitution
Inject immediately or refrigerate and use within 24–48 hours; do not freeze.
Supplies
| Peptide vials | 10-31 vials (10 mg blend each) for an 8-16 week protocol |
|---|---|
| Insulin Syringes (U-100) | 56-112 syringes for an 8-16 week protocol |
| Bacteriostatic Water (10 mL bottles) | 3-10 bottles for an 8-16 week protocol |
| Alcohol Swabs | Minimum 200-count box for proper hygiene |
Important notes
- Always use sterile insulin syringes and dispose of them in a sharps container.
- Rotate injection sites regularly (abdomen, thighs, upper arms) to prevent local irritation and lipohypertrophy.
- Inject slowly and allow a few seconds before withdrawing the needle.
- Maintain a record of your daily dose and injection site rotation for consistency.
- If injecting larger volumes (over 1.0 mL), consider splitting the dose across two injection sites for comfort.
Frequently asked questions
Why combine Tesamorelin and Ipamorelin instead of using just one?
Combining Tesamorelin, a GHRH analog, with Ipamorelin, a ghrelin mimetic, creates a synergistic effect that significantly amplifies growth hormone release beyond what either peptide could achieve alone. This dual action is designed for more robust stimulation of the growth hormone pathway.
Can I adjust the dosing schedule if I don't want to titrate up?
While the gradual titration schedule is recommended to allow the body to adapt and assess tolerability, some protocols may use a flat dose. However, this specific protocol outlines a gradual increase over several weeks. Always consult with a qualified professional for personalized advice.
What is the best time of day to inject this blend?
Evening or bedtime administration is often suggested. This timing can align with the body's natural nocturnal growth hormone secretion patterns, potentially optimizing the peptide's effects.
How crucial is it to rotate injection sites?
Rotating injection sites daily is very important. It helps prevent localized irritation, tissue damage, and the formation of visible lumps or fatty deposits known as lipohypertrophy, ensuring better absorption and comfort over the course of the cycle.
Educational reference only. These figures summarise how Tesamorelin + Ipamorelin is commonly described in research literature and supplier documentation, including the Tesamorelin + Ipamorelin listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
CJC-1295 DAC + Ipamorelin Stack (CJC-1295 (2 mg) + Ipamorelin (5 mg))
Amplify growth hormone production with this synergistic peptide stack.
Ipamorelin (5 mg Vial)
Selective growth hormone secretagogue for lean mass, recovery, and fat metabolism.
CJC-1295 + GHRP-2 (10 mg Blend)
Synergistic blend for sustained growth hormone release and IGF-1 elevation.